New York State Common Retirement Fund Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

New York State Common Retirement Fund lowered its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 7.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 14,549 shares of the company’s stock after selling 1,100 shares during the quarter. New York State Common Retirement Fund’s holdings in Kymera Therapeutics were worth $585,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in KYMR. Blue Trust Inc. boosted its holdings in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after acquiring an additional 270 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in Kymera Therapeutics by 1.7% during the 4th quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock worth $1,649,000 after purchasing an additional 684 shares during the period. KBC Group NV grew its position in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Kymera Therapeutics by 8.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock valued at $534,000 after purchasing an additional 915 shares during the period.

Analysts Set New Price Targets

Several brokerages recently issued reports on KYMR. HC Wainwright boosted their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Wells Fargo & Company raised Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Leerink Partners restated an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Friday, December 27th. Stephens reiterated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Finally, BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $56.69.

Insider Buying and Selling at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ellen Chiniara sold 2,241 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,788 shares of company stock valued at $455,202. Corporate insiders own 15.82% of the company’s stock.

Kymera Therapeutics Trading Up 1.7 %

NASDAQ KYMR opened at $30.68 on Wednesday. The company has a 50-day moving average price of $38.60 and a two-hundred day moving average price of $43.56. Kymera Therapeutics, Inc. has a 52 week low of $29.07 and a 52 week high of $53.27. The stock has a market cap of $1.99 billion, a price-to-earnings ratio of -13.11 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. As a group, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.